Acurion's All-Star Team-Up Signals Major Push in AI Cancer Diagnostics

SAN DIEGO, CA – June 17, 2026 – In the world of biotech, a press release announcing new hires and a seed funding round is standard fare. But occasionally, one lands with the force of a strategic masterstroke. Acurion’s announcement today is one such case. The precision oncology firm has not only closed an oversubscribed $4.3 million seed round but has also assembled a leadership and advisory board that reads like a who's who of the technology, diagnostics, and oncology sectors. This isn't just about adding headcount; it's a calculated move to arm the company with the exact expertise needed to navigate the treacherous path from a promising prototype to a profitable, market-ready product.

For investors and industry watchers, Acurion’s latest moves provide a compelling case study in building a company for commercial success. By attracting top-tier talent from companies like Qualcomm, Yale Cancer Center, and Bristol Myers Squibb, the San Diego-based startup is signaling its aggressive intent to fast-track its AI-powered OncoGaze™ platform from the lab to the clinic, potentially transforming how cancer biomarkers are detected.

A Power Play in Talent and Expertise

A company's potential is often measured by the talent it attracts, and Acurion has stacked its deck with proven winners. The appointments go far beyond typical startup hires, targeting the specific hurdles of commercialization, regulation, and scalability.

Leading the commercial charge is Mike Hoerres, the new Advising Chief Commercial Officer. Hoerres's track record is pristine; as CEO of Cernostics, he successfully navigated the development and commercialization of the TissueCypher diagnostic test, culminating in the company's acquisition by Castle Biosciences. His experience is a direct injection of know-how for turning a complex diagnostic tool into a revenue-generating asset. He is complemented by David Schlessinger, the new VP of Product Development, who comes from leadership roles at molecular diagnostics giants Natera and Exact Sciences. Schlessinger’s career has been defined by shepherding advanced diagnostics through the entire lifecycle, from the development bench to commercial launch.

Critically, Acurion has also brought on Heather Jalisi as VP of Regulatory Affairs. With over two decades of experience at firms like Becton Dickinson and Leica Biosystems, Jalisi is equipped to steer Acurion’s AI platform through the FDA's complex regulatory labyrinth for medical devices—a crucial milestone for any company in this space. Rounding out the operational team are Leandra Boysen as Sr. Director of Strategic Partnerships, tasked with building the clinical and industry collaborations essential for validation and adoption, and Rick Schmitt, a technology veteran from Illumina and Neurocrine, who will oversee the scaling of Acurion's tech infrastructure.

Perhaps most telling are the names joining the advisory and board ranks. The appointment of Dr. Irwin Jacobs, co-founder and former CEO of Qualcomm, as a Strategic Scientific Advisor is a monumental vote of confidence. Dr. Jacobs is a legend in the technology world, renowned for scaling complex systems into global standards. His involvement suggests Acurion possesses technology with the potential for massive impact. On the clinical front, Dr. Eric Winer, Director of the Yale Cancer Center and former president of ASCO, brings unparalleled oncology expertise, ensuring OncoGaze™ is developed to meet the real-world needs of clinicians and patients. These titans are joined by Dr. Ho Sung Cho, a former SVP at Bristol Myers Squibb, and Dr. Tomas Koch, a 30-year McKinsey veteran and Chairman of TK Partners, who joins the Board of Directors.

"Building lasting institutions requires both a telescope and a microscope - a long-term vision of the possible and a razor-sharp focus on quarterly results," stated Dr. Koch. This sentiment perfectly encapsulates Acurion's strategy: pairing a disruptive vision with a team built for rigorous execution.

OncoGaze: Bypassing the Genomic Bottleneck

The all-star team has been assembled to commercialize a truly innovative technology. Acurion’s OncoGaze™ platform aims to solve a fundamental problem in modern cancer care: the biomarker bottleneck. While targeted therapies have revolutionized treatment, they depend on identifying specific molecular markers in a patient's tumor. The current gold standard, genomic sequencing, is powerful but often slow, expensive, and requires additional tissue, creating access disparities and life-threatening delays.

Acurion's approach sidesteps this entirely. The OncoGaze™ platform uses sophisticated AI algorithms to analyze the digital images of routine pathology slides that are already part of standard cancer diagnosis. It extracts biomarker insights directly from the tissue's morphology, providing what the company calls an “instantaneous, scalable and accessible approach to precision medicine.”

This method, which builds on the foundational cancer genomics research of co-founder and CSO Dr. Ludmil Alexandrov, could democratize precision oncology. By leveraging existing clinical workflows and materials, it has the potential to deliver critical biomarker information to oncologists in a fraction of the time and cost, regardless of a hospital's access to advanced molecular labs. This would enable more patients to receive the right targeted therapy faster, directly addressing a major unmet need in patient care.

From Seed Funding to Clinical Reality

The $4.3 million in oversubscribed seed funding is the fuel for this commercial engine. CEO Rick Fultz emphasized that the financing will support the company's next growth phase, including clinical validation, continued platform development, and regulatory preparations. These are the critical, capital-intensive steps that separate a promising idea from a market-approved product.

"These additions reflect the caliber of expertise required to build clinically meaningful AI tools capable of transforming patient care," said Fultz. "We have assembled a team with deep experience across oncology, diagnostics, regulatory strategy, and enterprise technology to support Acurion's next phase of growth."

By securing this capital and leadership team, Acurion has successfully navigated a key early milestone on its commercialization journey. The company is now positioned to execute its clinical and regulatory strategy, with the clear goal of bringing OncoGaze™ into routine clinical use. With expectations to announce additional clinical partnerships later this year, Acurion is a company that has moved firmly into the spotlight, demonstrating a clear and compelling strategy for turning its innovative prototype into tangible profit and, more importantly, improved patient outcomes.